The allosteric inhibitor CDIBA, which features an indole core structure, binds non-competitively and reversibly to the METTL3-METTL14 enzyme complex, and compound 43n optimized from CDIBA exhibits significant antiproliferative efficacy against acute myeloid leukemia (AML) cells (89). Here, METTL3 is linked to acute myeloid leukemia.